期刊文献+

HPV E6/E7 mRNA检测在宫颈癌筛查中的应用 被引量:4

Detection of HPV E6/E7m RNA in paraffin-embedded samples and exfoliated cells in cervical cancer cases
原文传递
导出
摘要 目的通过检测同一宫颈上皮内癌变或宫颈癌疑似病例宫颈石蜡包埋样本及脱落细胞中HPV E6/E7 m RNA的水平,分析两种检测结果的差异,探讨二者在宫颈癌筛查的应用价值。方法对302例宫颈上皮内癌变或宫颈癌疑似病例分别取宫颈活检组织及脱落细胞,两类标本均采用b DNA技术进行HPV E6/E7 m RNA检测,同时行病理学检查,并对检测的阳性率及灵敏度、特异度做出统计学分析。结果石蜡包埋组织检测HPV E6/E7 m RNA的阳性率为48.7%,高于脱落细胞的阳性率40.1%(χ2=4.192,P<0.05)。石蜡包埋组织检测HPV E6/E7m RNA对诊断的灵敏度为75.0%,高于脱落细胞的61.4%(χ2=5.046,P<0.05);石蜡包埋组织检测HPV E6/E7 m RNA对诊断的特异度为81.2%,脱落细胞为77.1%,二者差异无统计学意义(χ2=0.641,P>0.05)。结论检测石蜡包埋样本中的HPV E6/E7 m RNA,可更加精确预测宫颈病变进展风险,对宫颈癌筛查工作具有更好的临床意义。 Objective To analyze the value of HPV E6/E7mRNA between cervical exfoliated cells and paraffinembedded samples in the same patient and discuss the application value between them in cervical cancer screening. Methods Cervical biopsy tissues and exfoliated cells were collected from 302 samples and bDNA technology was used to detect the presence of HPV E6/E7 mRNA in two kinds of specimens and the positive rate, the sensitivity and specificity were statistically analyzed. Results The positive rate of paraffin-embedded samples was higher than that of cervical exfoliated cells (x^2= 4.192,/9〈0.05). The sensitivity in diagnosis of HPV E6/E7 mRNA in paraffin-embedded samples was higher that that in cervical exfoliated ceils without significant difference between them in diagnostic sensitivity(x^2 = 0.641, P〉0.05). Conclusion Detection of HPV E6/E7 mRNA from paraffin-embedded samples and foliated cells is a more accurate method for predicting risk of cervical lesions and it possesses clinical significance for screening of cervical lesions.
出处 《中国热带医学》 CAS 2014年第12期1493-1495,共3页 China Tropical Medicine
关键词 人乳头瘤病毒 宫颈肿瘤 E6/E7mRNA 石蜡包埋 bDNA技术 Human papillomavirus Uterine cervical neoplasms Er/E7 mRNA Paraffin-embedded Branch-DNA
  • 相关文献

参考文献1

二级参考文献14

  • 1刘彬,陈汶,任生达,刘新伏,马俊飞,崔剑峰,王秀荣,陈凤,乔友林.液基细胞学剩余标本筛查子宫颈病变中人乳头状瘤病毒DNA的应用[J].中华检验医学杂志,2005,28(5):495-497. 被引量:18
  • 2Moody CA,Laimins LA.Human papillomavirus oncoproteins:pathways to transformation. Nature Reviews Cancer . 2010
  • 3Cogliano V,Baan R,Straif K,et al.Carcinogenicity of human papillomaviruses. The Lancet Oncology . 2005
  • 4McCloskey R,Menges C,Friedman A,et al.Human papillomavirus type16E6/E7upregulation of nucleophosmin is important for proliferation and inhibition of differentiation. Journal of Virology . 2010
  • 5Ratnam S,Coutlee F,Fontaine D,et al.Clinical performance of the Pretect HPV-Proofer E6/E7mRNA assay in comparison with that of the Hybrid Capture2test for identification of women at risk of cervical cancer. Journal of Clinical Microbiology . 2010
  • 6Yang W,Maqsodi B,Ma Y,et al.Direct quantification of gene expression in homogenates of formalin-fixed,paraffin-embedded tissues. Biotechniques . 2006
  • 7Hovland S,Muller S,Skomedal H.E6/E7 mRNA expres-sion analysis:A test for the objective assessment of cervi-cal adenocarcinoma in clinical prognostic procedure. International Journal of Oncology . 2010
  • 8Rampias T,Boutati E,Pectasides E,et al.Activation of Wntsignaling pathway by human papillomavirus E6 and E7 onco-genes in HPV16-positive oropharyngeal squamous carcinomacells. Molecular Cancer Research . 2010
  • 9Munoz N,Bosch FX,de Sanjose S,et al.Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Homeopathy . 2003
  • 10Nicolas FS,Andrea T,Eliane DF,et al.Viral load as a predictor of the risk of cervical intraepithelial neoplasia. International Journal of Cancer . 2003

共引文献28

同被引文献27

  • 1冯淑瑜,张彦娜,刘建刚.宫颈癌淋巴结转移的高危因素及预后分析[J].癌症,2005,24(10):1261-1266. 被引量:71
  • 2宋恩霖,俞薇薇,熊小亮.宫颈癌预后的研究进展[J].实用临床医学(江西),2006,7(12):191-193. 被引量:9
  • 3Colombo N,Carinelli S,Colombo A,Marini C,Rollo D and Sessa C.Cervical cancer:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2012,23(7):vii27-32.
  • 4Arbyn M,Castellsague X,de Sanjose S,et al.Worldwide burden of cervical cancer in 2008[J].Ann Oncol,2011,22(12):2675-2686.
  • 5Tao X,Hu W,Ramirez PT and Kavanagh JJ.Chemotherapy for recurrent and metastatic cervical cancer[J].Gynecol Oncol,2008,110(3 Suppl 2):S67-71.
  • 6Kruse AJ,Skaland I,Janssen EA,et al.Quantitative molecular parameters to identify low-risk and high-risk early CIN lesions:role of markers of proliferative activity and differentiation and Rb availability[J].Int J Gynecol Pathol,2004,23(2):100-9.
  • 7Pietrzak B,Mazanowska N,Ekiel A.M.,et al.Prevalence of high-risk human papillomavirus cervical infection in female kidney graft recipients:an observational study[J].Virol J,2012,9(9):117-122.
  • 8Katase K,Teshima H,Hirai Y,et al.Natural history of cervica human papillomavirus lesios[J].Intervirology,1995,38(3-4):192-194.
  • 9Czegledy J,Veress G,Konya J,et al.Genital human papillomavirus(HPV)infection in Hungarian women[J].Aacta Microbiologyca Hungarica,1993,40(2):115-122.
  • 10Lie AK,Kristense G.Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical cancinoma[J].Expert Rev Mol Diagn,2008,8(4):405-415.

引证文献4

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部